Qube Research & Technologies LTD Arcellx, Inc. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Arcellx, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 50,251 shares of ACLX stock, worth $4.48 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
50,251
Previous 144,636
65.26%
Holding current value
$4.48 Million
Previous $7.98 Million
47.43%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding ACLX
# of Institutions
205Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$356 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$346 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$334 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$313 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$219 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.9B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...